XVIVO Q2 Update: Another roaring quarter - Redeye

XVIVO delivered an organic growth surprise at 32% (CER, 32% in Q1) during Q2 a quarter, with a substantial contribution from both the thoracic and abdominal business, whilst the OPEX level is contained. The outlook remains positive, and the critical US Heart study is underway. Our updated Base Case is SEK 575 (460) with a Bull Case of SEK 1,100 (925) and a Bear Case of SEK 165 (115).

Länk till analysen i sin helhet: https://www.redeye.se/research/1021938/xvivo-q2-update-another-roaring-quarter?utm_source=finwire&utm_medium=RSS